<DOC>
	<DOC>NCT00152256</DOC>
	<brief_summary>The objective of this study is to determine the safety and efficacy effects of two doses of asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to premenopausal subjects with symptomatic uterine leiomyomata.</brief_summary>
	<brief_title>A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids</brief_title>
	<detailed_description>No medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids. Asoprisnil (10 mg and 25mg) is being evaluated in a Phase 3 program to establish long term safety and effectiveness and therefore provide women with a medical alternative to surgery.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<criteria>Premenopausal women History of regular menstrual cycles (2142 days) Diagnosis of uterine fibroid(s) Abnormal vaginal bleeding associated with uterine fibroids Otherwise in good health Subject must have at least one fibroid with a diameter ≥ 2 cm or multiple small fibroids with a uterine volume of ≥ 200 cm3 Less than 3 months postpartum and postlactation Previous myomectomy within 1 year Any abnormal lab or procedure result the studydoctor considers important Severe reaction(s) to or are currently using any hormone therapy History of osteoporosis or other bone disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>53 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Symptomatic Uterine Fibroids</keyword>
	<keyword>Excessive Uterine Bleeding</keyword>
	<keyword>Uterine Hemorrhage</keyword>
</DOC>